Neurology Central

Multiple sclerosis therapy: US, EU regulators accept marketing applications for siponimod

Novartis (Basel, Switzerland) have announced US FDA and EMA filing acceptance for their new drug application and marketing authorization application of siponimod to treat secondary progressive multiple sclerosis (SPMS) in adults. The filing application was supported by Phase III EXPAND data, which demonstrated siponimod to have beneficial effects on disability, relapses and magnetic resonance imaging disease activities in individuals with SPMS.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.